Core Scientific Q3 Profit Beat Masks $959M Cash Burn
Core Scientific reported its first profitable quarter with Q3 EPS of $0.36, beating consensus by 8,759%, yet shares fell as the market weighed the real constraint: negative $959M trailing free cash fl
CORZ Q3 Beat Masks $959M FCF Burn, Insider Exits
NEW YORK, November 9 —
When Core Scientific, Inc. (CORZ) reported its first profitable quarter, the market responded by selling the stock. The 8-K filed November 5, 2026 showed Q3 EPS of $0.36 against an essentially flat consensus, an 8,759% beat, yet shares fell anyway: the market's verdict that a GAAP milestone is not a cash-flow milestone.
- Q3 EPS of $0.36 beat an essentially flat consensus by 8,759%; first profitable quarter per 8-K filed November 5, 2026.
- Free cash flow: -$959M trailing 12 months; $4.41B total debt versus $0.80B cash.
- Insider Todd Duchene sold ~110,000 shares in 11 consecutive weekly tranches, August 24 through November 2.
The Pivot Works; The Balance Sheet Does Not
Core Scientific operates Colocation, Self-Mining, and Hosted Mining segments, one of several former bitcoin miners pivoting toward AI data center hosting. The Colocation arm, selling space, power, cooling, and security to customers running machine learning workloads, is the pivot's intended engine. Trailing 12-month revenue of $0.59 billion is up 187.1% year-over-year, and 44.1% gross margin indicates the direction is working. Operating cash flow of $454 million disappears into a capital program that leaves free cash flow at -$959 million. CEO Adam Sullivan called "capital the throttle on all new development" in AI data centers: a phrase that describes Core Scientific's own predicament with equal accuracy.
An Insider Sold Through the Entire Decline
Todd Duchene sold approximately 10,000 shares per week in 11 consecutive tranches between August 24 and November 2, 2026, totaling roughly 110,000 shares, per Form 4 filings. His realized price fell from $18.67 on September 8 to $12.78 on November 2: he sold through the entire decline. A 10b5-1 plan could make the mechanical cadence innocent. But the market does not distinguish: with 26.9% of float already short, there is a large contingent positioned to agree with the insider's decision to exit rather than hold through what turned out to be an earnings beat.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| CORZ | $4.1B | 73.8x | -39.0% |
| CIFR | $3.1B | 22.8x | -66.7% |
| WULF | $6.2B | 343.1x | -20.5% |
| BTDR | $1.8B | n/a | -65.9% |
| HUT | $6.7B | n/a | +11.6% |
| KEEL | $1.2B | n/a | -47.8% |
The Re-Rating Needs Cash, Not EPS
The forward P/E of 37.4x and a consensus target of $27.38 (more than double the current ) build the bull case; a stress-test through the DCF calculator shows how sensitive that target is to discount-rate shifts. B. Riley maintained its Buy on November 9 while trimming from $31 to $27. FCF trajectory is the specific number to watch next quarter: if it turns materially less negative, the multiple re-rates; if it stays negative at $4.41 billion in debt, the profit beat is an accounting milestone, not a capital structure event. Run the free Core Scientific, Inc. deep-dive → /stock/corz.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Core Scientific stock fall after its earnings beat?
The market focused on free cash flow, not earnings per share. Core Scientific's trailing 12-month free cash flow was negative $959M, while operating cash flow of $454M disappears into a heavy capital program for AI data center expansion. As CEO Adam Sullivan said, "capital is the throttle on all new development"—a predicament Core Scientific faces with its own growth.
How much free cash flow did Core Scientific burn?
Negative $959M over the trailing 12 months. Operating cash flow of $454M evaporates into a capital program, leaving the company in a negative FCF position against $4.41B in total debt and only $0.80B in cash.
Why is insider selling significant?
Todd Duchene sold approximately 110,000 shares in 11 consecutive weekly tranches between August 24 and November 2, realizing a price decline from $18.67 to $12.78. He sold through the entire decline, with 26.9% of float already short, a large contingent positioned to agree with his decision to exit.
What would justify the $27.38 consensus price target?
Analysts cite a forward P/E of 37.4x as the bull case, but the multiple only re-rates if free cash flow turns materially less negative. As long as FCF stays negative with $4.41B in debt, the profit beat remains an accounting milestone, not a capital structure event.
Core Scientific reported its first profitable quarter in Q3 2026, beating EPS estimates by more than 8,700%, yet shares fell on the news. The profit sits atop $4.41 billion in debt and $959 million in negative free cash flow — leaving investors to judge whether the earnings milestone is genuine inflection or accounting artifact.